Background:   HOXA9 is a transcription factor with a central role in both haemopoiesis and leukaemia. High levels of HOXA9 expression in haemopoietic cells is a characteristic feature of acute myeloid leukaemia (AML), and may be sufficient to cause this disease. Overexpression of Hoxa 9 markedly expands hematopoietic stem cells. HOXA9 expression changes dramatically with age - a uniformly low level of expression during early adulthood is replaced by a frequently very high expression in adults over sixty.

Description: Rabbit polyclonal to HOXA9

Immunogen: KLH conjugated synthetic peptide derived from HOXA9

Specificity:  ·Reacts with Human, Mouse and Rat.

.·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 30 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.